Physician profile
Zain Raza
NPI 1184119802
$1,649.68
in general payments reported to CMS, 2019-2025
15 companies · $485 in 2025
The $485 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $381 · 2023: $455 · 2024: $328 · 2025: $485.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,104 · Education: $164.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,104.48 |
| Education | $163.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ardelyx, INC. | $191.44 | 2023-2025 | Ibsrela |
| Janssen Biotech, INC. | $163.99 | 2024-2025 | Tremfya, Stelara |
| Novo Nordisk INC | $139.86 | 2025 | Wegovy |
| Gilead Sciences, INC. | $134.20 | 2023-2025 | Vemlidy |
| Genzyme Corporation | $130.77 | 2022 | |
| Abbvie INC. | $124.14 | 2025 | |
| Horizon Therapeutics Plc | $123.32 | 2022 | |
| Phathom Pharmaceuticals, INC. | $116.31 | 2024 | Voquezna |
| Astrazeneca Pharmaceuticals LP | $107.58 | 2023 | Farxiga |
| Intercept Pharmaceuticals, INC. | $106.27 | 2022 | |
| Travere Therapeutics, INC. | $88.18 | 2023 | |
| Mallinckrodt Hospital Products INC. | $84.70 | 2024 | Terlivaz |
| Boston Scientific Corporation | $67.93 | 2022-2024 | Apollo Esg Nxt System |
| Takeda Pharmaceuticals U.S.A., INC. | $40.19 | 2025 | Entyvio |
| Regeneron Healthcare Solutions, INC. | $30.80 | 2025 | Dupixent |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Zain Raza listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.